Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583395 | 1.00 | GAA (0.51) | GAAMEN1KMT2APOLBLMNA | |
| SCHEMBL10100023 | 0.86 | KCNQ2 (0.40) | GAA | |
| SCHEMBL583786 | 0.86 | KCNQ2 (0.40) | GAA | |
| SCHEMBL582937 | 0.86 | KCNQ2 (0.40) | GAA | |
| SCHEMBL14192012 | 0.86 | GAA (0.49) | GAAMEN1KMT2APOLBLMNA | |
| SCHEMBL582577 | 0.84 | MEN1 (0.49) | GAAMEN1KMT2APOLBLMNA | |
| SCHEMBL582767 | 0.84 | MEN1 (0.57) | GAAMEN1KMT2APOLBLMNA | |
| SCHEMBL582392 | 0.84 | MEN1 (0.57) | GAAMEN1KMT2APOLBLMNA | |
| SCHEMBL583730 | 0.83 | GAA (0.55) | GAAMEN1KMT2APOLBLMNA | |
| SCHEMBL583586 | 0.83 | GAA (0.55) | GAAMEN1KMT2APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755572-B1 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-02-15 | — | — | EP | claimed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | claimed |
| JP-2008501800-A | — | — | 2008-01-24 | — | — | JP | claimed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | claimed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | claimed |
| EP-1755572-B1 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-02-15 | — | — | EP | disclosed |
| US-7763659-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7629367-B2 | Tissue-selective androgen receptor modulators (SARMs); male hypogonadism, prostate cancer, benign prostate hyperplasia, sarcopenia, rheumatoid arthritis and osteoarthritis; N-((5-cyclopropyl-2-fluoropyridin-3-yl)methyl)-2-phenylbutanamide for example | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | GAA 2879/4885MEN1 3096/4885KMT2A 1189/4885 |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | GAA 2879/4885MEN1 3096/4885KMT2A 1189/4885 |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | GAA 2839/4885MEN1 3173/4885KMT2A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.